Table 4

Characteristics of patients in the matched control study

CharacteristicIFM 2005-01 (n = 115)IFM Bor-HDM (n = 46)
Sex, M/F, n 60/55 24/22 
Median age, y (range) 58 (32-65) 58 (40-65) 
Isotype, %   
    IgG 69 67 
    IgA 20 20 
    LC 
    Others 
ISS stage, %   
    I 48 52 
    II 36 22 
    III 16 26 
Median β2-microglobulin level, mg/L (range) 3.3 (1.3-41.9) 3.3 (1.7-15.7) 
Median albumin level, g/L (range) 39 (22-54) 39 (18-52) 
FISH analysis, n/evaluable patients (%)   
    del(13q) 59/113 (52) 21/42 (50) 
    del(17p) and/or t(4;14) 14/113 (12) 8/37 (21) 
Frontline treatments, n (%)*   
    VAD 70 (61) 28 (61) 
    Bor/Dex 45 (39) 18 (39) 
Response to induction therapy, n (%)*   
    SD 15 (13) 6 (13) 
    PR 60 (52) 24 (52) 
    VGPR 35 (30) 14 (30) 
    CR 5 (5) 2 (5) 
CharacteristicIFM 2005-01 (n = 115)IFM Bor-HDM (n = 46)
Sex, M/F, n 60/55 24/22 
Median age, y (range) 58 (32-65) 58 (40-65) 
Isotype, %   
    IgG 69 67 
    IgA 20 20 
    LC 
    Others 
ISS stage, %   
    I 48 52 
    II 36 22 
    III 16 26 
Median β2-microglobulin level, mg/L (range) 3.3 (1.3-41.9) 3.3 (1.7-15.7) 
Median albumin level, g/L (range) 39 (22-54) 39 (18-52) 
FISH analysis, n/evaluable patients (%)   
    del(13q) 59/113 (52) 21/42 (50) 
    del(17p) and/or t(4;14) 14/113 (12) 8/37 (21) 
Frontline treatments, n (%)*   
    VAD 70 (61) 28 (61) 
    Bor/Dex 45 (39) 18 (39) 
Response to induction therapy, n (%)*   
    SD 15 (13) 6 (13) 
    PR 60 (52) 24 (52) 
    VGPR 35 (30) 14 (30) 
    CR 5 (5) 2 (5) 

Ig indicates immunoglobulin; LC, light chain; ISS, International Staging System; FISH, fluorescence in situ hybridization; VAD, vincristine, Adriamycin, and dexamethasone; Bor/Dex, bortezomib and dexamethasone; SD, stable disease; PR, partial response; VGPR, very good partial response; and CR, complete response.

*

Distributions are identical due to matching.

Close Modal

or Create an Account

Close Modal
Close Modal